DV
Dividend Vision

AGEN — Agenus Inc

Agenus Inc (AGEN)

Total return is -99.9% over the past 26.5 years, 868.8 points behind SPY at 768.9%. Its deepest 1-year drawdown was 45.4%.

Agenus Inc. is a clinical-stage biotechnology company developing immunotherapies for cancer and infectious diseases, including checkpoint inhibitor antibodies, vaccine adjuvants, and bispecific antibodies in various stages of clinical trials. The company does not currently distribute dividends. Agenus appeals primarily to investors seeking exposure to biotechnology development risk rather than income generation.

AGEN key facts

Asset type
Stock
Asset class
Equity
Inception date
02/04/2000
Last close
$7.32
Market cap
$208,628,592
Average volume
1251900.0
Beta
1.554
Payout ratio
0.0
P/E ratio
2.4439
Forward P/E
2.2878
EPS
$2.05